OncoTriage. Поиск наилучшего лечения для вашего пациента

Острые лейкозы

НОВАЯ СТАТЬЯ

Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients.

Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by poor survival outcomes...

DOI: 10.1186/s12920-025-02130-7

Giri AK, Lin J, Kyriakidis K, Tripathi G, Almusa H

BMC medical genomics, 2025-04-06

НОВАЯ СТАТЬЯ

Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML.

Venetoclax (VEN)--based induction therapy has demonstrated considerable promise in treating acute myeloid leukemia (AML); however, the optimal VEN-based combination therapy remains to be established...

DOI: 10.1007/s00277-025-06250-z

Song BQ, Kong X, Liu Y, Pu Y, Zhang J, Wu DP, Qiu HY

Annals of hematology, 2025-04-06

НОВАЯ СТАТЬЯ

A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by elevated mortality...

DOI: 10.1016/j.intimp.2025.114268

Yang J, Liu Q, Zhang X, Jing Y, Le N, Li M, Xu L, Zhao W, Huang S, Liu D, Dou L

International immunopharmacology, 2025-04-06

НОВАЯ СТАТЬЯ

Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.

Methodological advancements now allow older adults with AML to receive allografts although conflicting data exist regarding relative outcomes across age groups and benefits of different conditioning intensities...

DOI: 10.1038/s41409-025-02516-2

Vo PT, Sandmaier BM, Othus M, Ali N, Rodríguez-Arbolí E, Orvain C, Davis C, Basom RS, Storb R, Walter RB

Bone marrow transplantation, 2025-04-06

НОВАЯ СТАТЬЯ

Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.

Umbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to be treated safely...

DOI: 10.1038/s41409-025-02508-2

Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N, Onizuka M, Miyakoshi S, Tanaka M, Takahashi S, Hayashi M, Kawakita T, Uehara Y, Ota S, Izumi T, Sawa M, Nishida T, Katayama Y, Nagafuji K, Kato K, Ichinohe T, Atsuta Y, Yanada M

Bone marrow transplantation, 2025-04-06

CAR T cell therapy for treatment of Acute Myeloid Leukemia, Advances and Outcomes.

Despite recent U.S. FDA approval of multiple therapies for patients with acute myeloid leukemia (AML), clinical outcomes for those patients continue to remain poor..

DOI: 10.1016/j.ymthe.2025.03.052

Khalifeh M, Hopewell E, Salman H

Molecular therapy : the journal of the American Society of Gene Therapy, 2025-04-05

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.

CAR-T and blinatumomab therapies demonstrate comparable safety and efficacy as bridging treatments to HSCT in patients with R/R B-ALL. Further studies are needed to optimize these treatment strategies.

DOI: 10.1186/s12967-025-06399-1

Cao W, Li N, Wang G, Xu H, Yang Y, Wang J, Xu J, Li Y, Zhang Y, Cao Y, Wang N

Journal of translational medicine, 2025-04-05

Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes.

Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis...

DOI: 10.1182/blood.2024027244

Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza AI, Root JL, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Abbas HA

Blood, 2025-04-05

Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.

Our retrospective single-center analysis suggests that approximately half of the patients with AML who experience LVEF decline during induction will not recover. Ischemic events during treatment were predictive of nonrecovery. The use of GDMT may improve prognosis for some patients. Given the impact of recovery, we propose the prospective verification and establishment of cardiac management algorithms in patients with AML.

DOI: 10.1200/OP-24-00734

Wu M, Russell K, Shaw CM, Halpern AB, Ghiuzeli C, Appelbaum JS, Hendrie P, Walter RB, Percival MM

JCO oncology practice, 2025-04-05

HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation.

Herein, we identified that HDAC11 is involved in the pathogenesis of AML and is a potential therapeutic target for AML...

DOI: 10.1021/acs.jmedchem.4c02550

Yang M, Zhao W, Zhang J, Liu L, Tian S, Miao Y, Jia Y, Wang L, Chai Q, Wang Q, Liu F, Zhang Y, You X

Journal of medicinal chemistry, 2025-04-05

Patients with high-risk acute promyelocytic leukemia need maintenance therapy for one year - the CONS.

Not available..

DOI: 10.3324/haematol.2025.287418

Iland HJ

Haematologica, 2025-04-05

Patients with high-risk acute promyelocytic leukemia need maintenance therapy for one year - the PROS.

Not available..

DOI: 10.3324/haematol.2025.287417

Tallman MS

Haematologica, 2025-04-05

Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults.

To the best of our knowledge, we present the largest reported cohort of patients treated with siltuximab for CRS following CAR T-cell therapy for B-ALL. Siltuximab's safety profile and its inhibition of IL-6 effects suggest that it should be investigated as first-line therapy in prospective clinical trials.

DOI: 10.1186/s40164-025-00638-3

Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Mirones Aguilar I, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirr

Experimental hematology & oncology, 2025-04-04

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.

У данной статьи нет абстракта.

DOI: 10.1038/s41408-025-01265-1

Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning

Blood cancer journal, 2025-04-04

Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.

T-cell acute lymphoblastic leukemia (T-ALL) is a very rare hematological malignancy with a poor prognosis...

DOI: 10.1007/s10238-025-01638-7

Xu F, Bao X, Huang W, Zhou K

Clinical and experimental medicine, 2025-04-04

Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib.

Ponatinib may prolong quality-adjusted survival compared with imatinib, supporting the benefit-risk profile of ponatinib as a front-line treatment for Ph+ ALL.

DOI: 10.1002/cam4.70780

Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Rane D, Guo S

Cancer medicine, 2025-04-04

Outcome of Induction Chemotherapy with the Berlin-Frankfurt-Munster-95 Regimen in Acute Lymphoblastic Leukemia Patients: A Quasi-Experimental Study.

Response to induction chemotherapy plays a major role in prognosis of acute lymphoblastic leukemia (ALL)...

Chowdhury N, Kabir A, Islam MM, Das S, Wasim M, Karim MN, Alam MM, Islam MN, Banik J, Fardous J, Hassan MK

Mymensingh medical journal : MMJ, 2025-04-04

Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients.

Compared to IV-DEC, C-DEC provides similar therapeutic exposure and efficacy with an optional safety profile, enhanced treatment adherence, reduced treatment burden, and required healthcare facilities compared to those associated with IV-DEC, providing a precious tool to manage older and unfit AML patients.

DOI: 10.1080/17474086.2025.2487605

Niscola P

Expert review of hematology, 2025-04-02

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.

In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.

DOI: 10.1002/cncr.35824

Nanni J, Azzali I, Papayannidis C, Mulè A, Audisio E, Martelli MP, Scappini B, Chiusolo P, Cambò B, Candoni A, Lunghi M, Albano F, Olivieri A, Fracchiolla N, Bernardi M, Romani C, Rigolin GM, Giannini MB, Bocchia M, Todisco E, Cilloni D, Bochicchio M

Cancer, 2025-04-04

Stable Expressed Mutants Predict a Poor Prognosis in Acute Myeloid Leukemia Patients Without Receiving Hematopoietic Stem Cell Transplantation.

У данной статьи нет абстракта.

DOI: 10.1002/mco2.70151

Zhang X, Liu L, Qin J, Ni X, Jin J

MedComm, 2025-04-03

INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Despite the limitations of retrospective studies, the INO-CD22 study highlights the favorable safety profile and clinical activity of IO within a real-world context.

DOI: 10.1002/cncr.35820

Papayannidis C, Petracci E, Zappasodi P, Fracchiolla N, Ciceri F, Sartor C, Roncoroni E, Di Raimondo F, Mattei D, Giannini MB, Lanza F, Gottardi M, Del Principe MI, Borlenghi E, Fumagalli M, Vallisa D, Sica S, Di Renzo N, Fabbiano F, Todisco E, de Fa

Cancer, 2025-04-04

Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.

Focused research in acute myeloid leukemia (AML) biology and treatment has led to the identification of new therapeutic targets and several new drug approvals over the last decade...

DOI: 10.1002/cncr.35806

Senapati J, Kadia TM, Daver NG, DiNardo CD, Borthakur G, Ravandi F, Kantarjian HM

Cancer, 2025-04-04

Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol.

Acute myeloid leukemia (AML) treatment relied on anthracyclines and cytarabine based intensive chemotherapy...

DOI: 10.1080/14796694.2025.2469487

Zhang Y, Wu M, Jin Z, Yang L, Huang X, Li W, Zhu H, Wang W, Chen Q, Liu L, Chen Z, Wang S, Li J

Future oncology (London, England), 2025-04-04

Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic review.

Frailty was predictive of poorer outcomes in patients with AML distinct from and complimentary to traditional disease prognostic schema. Routine implementation of frailty assessment could represent an important tool to risk stratify patients and improve clinical decision making.

DOI: 10.1016/j.jgo.2025.102196

Sia A, Chopra S, Ling VY, Fletcher J, Hubbard RE, Mollee P, Gordon E, Reid N, Hanjani LS

Journal of geriatric oncology, 2025-04-04

Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

The outcomes of patients with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HCT) remain poor despite many attempts at developing therapeutic strategies...

DOI: 10.1016/j.exphem.2025.104746

Tachibana T, Izumi A, Arai S, Takeda T, Hirose N, Tamai Y, Sato S, Hashimoto C, Fujimaki K, Ishii R, Sakai H, Yamazaki E, Inoue Y, Tanaka M, Nakajima H

Experimental hematology, 2025-04-04

Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.

We retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1)...

DOI: 10.1038/s41409-025-02527-z

Sanz J, Labopin M, Versluis J, Blaise D, Lazzari L, Montoro J, Van Gorkom G, von dem Borne P, Sandrine L, Rovira M, Reményi P, Chevallier P, Kwon M, Eder M, Vydra J, Brissot E, Spyridonidis A, Piemontese S, Mohty M, Ciceri F

Bone marrow transplantation, 2025-04-06

Umbilical Cord Blood Reduced Relapse but Increased Nonrelapse Mortality Compared to Matched Unrelated Donor Transplantation in Pediatric Acute Myeloid Leukemia With Active Disease: A CIBMTR 2008 to 2017 Analysis of Donor Source and Residual Disease.

Umbilical cord blood (UCB) and matched unrelated donors (MUD) are common alternative donor options in children with high-risk acute myeloid leukemia (AML)...

DOI: 10.1016/j.jtct.2025.01.889

Takahashi T, Wachter F, Alvarez Calderon F, Kapadia M, Qayed M, Keating AK

Transplantation and cellular therapy, 2025-04-04

Temporal Relationships Between General Self-Efficacy, Social Support and Health-Related Quality of Life Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A 9-Year Follow-Up Study.

The findings highlight the importance of self-efficacy and social support as potential buffering factors for HRQOL in adult survivors of childhood ALL over time.

DOI: 10.1002/pbc.31578

Aili K, Jarfelt M, Ivarsson A, Arvidsson S, Olsson M, Nygren JM

Pediatric blood & cancer, 2025-04-04

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.

Mutations in nucleophosmin 1 (NPM1) are diseased-defining genetic alterations encountered in approximately one-third of cases of acute myeloid leukemia (AML)...

DOI: 10.1002/ajh.27600

Chen EC, Shimony S, Luskin MR, Stone RM

American journal of hematology, 2025-04-04

Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.

VA-HAA may be an effective and safe salvage treatment for R/R T-ALL, and prospective clinical trials are needed to verify its specific clinical efficacy.

DOI: 10.1007/s12185-025-03915-3

Feng LS, Li HY, Tang A, Xu ML, Wang SB

International journal of hematology, 2025-04-04

Efficacy and Safety of Total Body Irradiation Versus Chemotherapy Conditioning for Hematopoietic Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Hematopoietic stem cell transplantation (HSCT) is a potentially curative option for adults with acute lymphoblastic leukemia (ALL) who have achieved remission...

DOI: 10.1016/j.clml.2024.12.007

Ans H, Amjad H, Nazir S, Cheema SS, Mistry D, Fatima T, Khan AY, Imtiaz MU, Khan FM, Khalid S, Rehman MEU, Faisal MS

Clinical lymphoma, myeloma & leukemia, 2025-04-03

Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.

Post-transplant tyrosine kinase inhibitors (TKIs) show promise in preventing relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)...

DOI: 10.1007/s12185-025-03917-1

Nishiwaki S, Terakura S, Morishita T, Goto T, Inagaki Y, Miyao K, Fukushima N, Hirano D, Tange N, Kurahashi S, Kuwatsuka Y, Kasai M, Iida H, Ozeki K, Sawa M, Nishida T, Kiyoi H

International journal of hematology, 2025-04-04

Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.

У данной статьи нет абстракта.

DOI: 10.1080/10428194.2024.2443017

Tessier S, McCullough KB, Gangat N, Begna KH, Saliba AN, Mangoankar AA, Shah MV, Hogan WJ, Patnaik MM, Al-Kali A, Alkhateeb HB

Leukemia & lymphoma, 2025-04-04

Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease.

Traditional risk factors, incorporating clinical and cytogenetic features, have been previously evaluated to stratify risks and guide treatment decisions. However, the prognostic strength of this stratified system is limited by the pediatric-inspired protocol background, making it difficult to identify patients with a high risk of relapse. Therefore, in the era of pediatric-inspired protocols, it is imperative to reassess traditional risk factors to identify patients at high risk of recurrence and mortality.In this study, we retrospectively evaluated the combination of MRD and IKZF1 to develop an efficient risk stratification tool for adult patients with B-ALL in the pediatric-inspired chemotherapy era. Moreover, allo-HSCT had distinct efficacy at different risk levels, which means that the decision to perform allo-HSCT may be well guided by this risk classification scheme.

DOI: 10.1016/j.jtct.2025.01.003

Deng S, Ou J, Chen J, Huang Z, Cai Z, Xu X, Tang B, Ding C, Li J, Lin R, Wang Z, Zhang T, Liu Q, Zhou H

Transplantation and cellular therapy, 2025-04-04

Omics approaches: Role in acute myeloid leukemia biomarker discovery and therapy.

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has the highest fatality rate...

DOI: 10.1016/j.cancergen.2024.12.006

Shafiei FS, Abroun S, Vahdat S, Rafiee M

Cancer genetics, 2025-04-04

Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.

FLT3 mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis...

DOI: 10.1111/ejh.14383

Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Rossi T, Neri A, Morabito F, Vigna E, Gentile M